| Literature DB >> 30974083 |
Kelsey E Noll1, Martin T Ferris2, Mark T Heise3.
Abstract
Host genetic variation has a major impact on infectious disease susceptibility. The study of pathogen resistance genes, largely aided by mouse models, has significantly advanced our understanding of infectious disease pathogenesis. The Collaborative Cross (CC), a newly developed multi-parental mouse genetic reference population, serves as a tractable model system to study how pathogens interact with genetically diverse populations. In this review, we summarize progress utilizing the CC as a platform to develop improved models of pathogen-induced disease and to map polymorphic host response loci associated with variation in susceptibility to pathogens.Entities:
Keywords: Collaborative Cross; genetics reference populations; immune genes; immunity; infection
Mesh:
Year: 2019 PMID: 30974083 PMCID: PMC6494101 DOI: 10.1016/j.chom.2019.03.009
Source DB: PubMed Journal: Cell Host Microbe ISSN: 1931-3128 Impact factor: 21.023
Figure 1Representative CC Funnels
CC founders were bred in funnel breeding schemes to produce progeny with genetic contributions from each of the eight founders, at which point they were inbred for generations until reaching near homozygosity. Many different funnels were set up, each to produce a unique CC RI line.
Figure 2Summary of Infectious Disease and Immunity QTLs Mapped in the CC
QTLs are shown mapped onto MGSCv37/mm9; genome positions for QTLs that were mapped on GSCv38/mm10 were converted to corresponding MGSCv37/mm9 coordinates.
Summary of Infectious Disease and Immunity QTL Mapped in the CC
| Chr | Start (Mb) | End (Mb) | Pathogen | Phenotype | Name | Sig | Population | Reference |
|---|---|---|---|---|---|---|---|---|
| 1 | 6.3 | 12.7 | survival day | Asprl7 | ∗ | pre-CC | ||
| 3 | 109.6 | 123.6 | survival day | Asprl6 | ∗ | pre-CC | ||
| 8 | 44.2 | 55.5 | survival day | Asprl1 | ∗∗∗ | pre-CC | ||
| 10 | 12 | 23 | survival day | Asprl4 | ∗∗ | pre-CC | ||
| 10 | 94.3 | 99 | survival day | Asprl2 | ∗∗∗ | pre-CC | ||
| 15 | 31 | 37.5 | survival day | Asprl3 | ∗∗∗ | pre-CC | ||
| 18 | 5.2 | 13.6 | survival day | Asprl5 | ∗ | pre-CC | ||
| 4 | 54.3 | 58.3 | day 2 survival | Kprl1 | ∗∗∗ | pre-CC | ||
| 8 | 29.7 | 33.6 | day 8 survival | Kprl2 | ∗∗∗ | pre-CC | ||
| 18 | 19.9 | 36.4 | day 8 survival | Kprl3 | ∗ | pre-CC | ||
| 1 | 74.1 | 81.8 | spleen bacterial load | StSl3b | ∗ | CC | ||
| 1 | 77.5 | 95.6 | spleen bacterial load | StSl3a | ∗ | CC | ||
| 6 | 77.1 | 90 | liver bacterial load | StSl4 | ∗ | CC | ||
| 8 | 11.3 | 17 | spleen bacterial load | StSl1 | ∗∗∗ | CC | ||
| 10 | 46.4 | 54 | spleen bacterial load | StSl2 | ∗∗ | CC | ||
| 17 | 80.5 | 91.1 | liver bacterial load | StSl5 | ∗ | CC | ||
| 1 | 21.7 | 29 | influenza A virus | pulmonary edema (conditioned on Mx1) | HrI3 | ∗∗∗ | pre-CC | |
| 7 | 89.1 | 96.7 | influenza A virus | weight loss | HrI2 | ∗∗∗ | pre-CC | |
| 15 | 77.4 | 86.6 | influenza A virus | airway neutrophils | HrI4 | ∗∗∗ | pre-CC | |
| 16 | 97.5 | 98.2 | influenza A virus | weight loss, viral titer, lung pathology score, clinical score, inflammation, airway damage, and expression modules | HrI1 | ∗∗∗ | pre-CC | |
| 3 | 18.3 | 26.7 | SARS-coronavirus | vascular cuffing | HrS1 | ∗∗∗ | pre-CC | |
| 13 | 52.8 | 54.9 | SARS-coronavirus | vascular cuffing (conditioned on HrS1) | HrS4 | ∗∗∗ | pre-CC | |
| 15 | 72.1 | 75.8 | SARS-coronavirus | eosinophilia | HrS3 | ∗∗ | pre-CC | |
| 16 | 31.6 | 36.7 | SARS-coronavirus | viral titer | HrS2 | ∗∗ | pre-CC | |
| 7 | 55.2′ | 117.2′ | SARS-coronavirus | viral titer | HrS7 | ∗∗∗ | CC-F2 | |
| 9 | 116.5′ | 124.6′ | SARS-coronavirus | day 3 weight loss | HrS6 | ∗∗∗ | CC-F2 | |
| 12 | 81.6′ | 108.5′ | SARS-coronavirus | viral titer | HrS8 | ∗∗∗ | CC-F2 | |
| 15 | 0′ | 64.4′ | SARS-coronavirus | hemorrhage | HrS9 | ∗∗∗ | CC-F2 | |
| 18 | 27.1′ | 58.7′ | SARS-coronavirus | day 3 and 4 weight loss, viral titer, and hemorrhage | HrS5 | ∗∗∗ | CC-F2 | |
| 3 | 129 | 130 | none | transitional B cells | ∗∗∗ | pre-CC | ||
| 4 | 148.8 | 151.1 | none | H57+ (total T cells) | ∗∗ | pre-CC | ||
| 6 | 23.2 | 23.8 | none | B cell to T cell ratio, H57+ (total T cells) CD19+ (total B cells) | ∗∗∗ | pre-CC | ||
| 6 | 88.1 | 92.7 | none | B cell to T cell ratio | ∗∗∗ | pre-CC | ||
| 7 | 136.5 | 138.6 | none | CD11c mean fluorescence intensity (MFI) | ∗∗∗ | pre-CC | ||
| 7 | 141.1 | 142.2 | none | CD4+/CD8+ ratio, CD4+ T cells, CD8+ T cells, and CD11c MFI | ∗∗∗ | pre-CC | ||
| 8 | 3.1 | 16.8 | none | CD23 MFI | ∗∗∗ | pre-CC | ||
| X | 100′ | 106′ | none | CXCR3+ T regulatory cells | HI2 | ∗∗∗ | CC-F1 | |
| X | 140′ | 145′ | none | ICOS+ T regulatory cells | HI3 | ∗∗∗ | CC-F1 | |
| X | 160′ | 171′ | none | CD73+ T regulatory cells | HI1 | ∗∗∗ | CC-F1 | |
| 2 | 26 | 31.1 | none | GP23 | ∗∗ | CC | ||
| 4 | 51.7 | 63.3 | none | GP15 | ∗∗ | CC | ||
| 7 | 149.6 | 151.4 | none | GP25 | ∗∗∗ | CC | ||
| 10 | 93 | 94.1 | none | GB17b | ∗∗∗ | CC | ||
| 12 | 114.5 | 117.9 | none | GP1, GP14, GP16, GP17a, and GP20 | ∗∗∗ | CC | ||
| 15 | 77.9 | 82.8 | none | GP6 and GP10 | ∗∗∗ | CC | ||
| 16 | 15 | 20.3 | none | GP17b | ∗∗∗ | CC |
Significance threshold levels: ∗<0.1, ∗∗0.1, ∗∗∗0.05. Genome coordinates marked with ′ refer to genome assembly GSCv38/mm10; otherwise, coordinates refer to MGSCv37/mm9.
Figure 3CC Workflow Schematic
(1) Small screen in a subset of CC strains (12–16), selected based on availability or a genotype of interest (e.g., MHC haplotype).
(2) Assess variation across strains, identify outliers, measure heritability, perform power calculations, and identify confounding variables and reassess experimental design if necessary.
(3) Perform a larger screen either in the full CC population or a targeted intercross. Following mapping, this can be repeated to follow-up on modifier alleles or other unexplained loci.
(4) Reassess variation, outliers, and heritability across mapping population.
(5) Map QTLs driving phenotype of interest; analyze founder haplotype effects if mapping is done in the CC.
(6) Rationally select candidate genes using different tools as applicable.
(7) Perform validation studies in vitro and/or in vivo to confirm effect of candidate gene on phenotype.